Highlights

  • Cochlear reported FY26 sales Revenue of about A$2.34 billion and underlying net profit of A$322.4 million.
  • Gross Margin was 71%, while Operating Cash Flow reached A$368 million and the full-year Dividend was A$3.45 per share.
  • Nucleus Nexa became the main implant choice in developed markets soon after launch, with an average price increase of about 3%.
  • FY27 guidance points to low single-digit constant-currency revenue growth and underlying net profit of A$330 million to A$350 million.

Cochlear Limited (ASX:COH) is a global provider of implantable hearing solutions, developing and commercialising cochlear implants, sound processors, bone-conduction systems and related services for people with hearing loss. Its FY26 result places the focus on the Nucleus Nexa platform, gross-margin discipline and whether planned cost savings can support Earnings recovery in FY27.

FY26 Earnings and Cash Flow

For the year ended 30 June 2026, Cochlear reported sales revenue of about A$2.34 billion, representing 2% constant-currency growth. Underlying net profit was A$322.4 million. Operating cash flow reached A$368 million, while the full-year dividend was A$3.45 per share, including a final dividend of A$1.30 per share franked at 85%.

Margin Pressure Remains Central

Gross margin was 71% in FY26. Management linked the outcome to product mix, Manufacturing overhead and currency movements. Services revenue increased 6% in constant currency, with developed markets up 13%, providing a Recurring Revenue stream alongside new system sales.

Nucleus Nexa Becomes a Key Product Driver

The Nucleus Nexa System was the most important product development in the FY26 result. Cochlear describes Nexa as a smart cochlear implant platform with upgradeable firmware. The company reported that Nexa represented more than 95% of implant sales in developed markets shortly after launch and was associated with an average price increase of about 3%.

Regional Conditions and Investment Spending

Regional performance was uneven. Western Europe revenue declined 8%, while emerging markets declined 2%, reflecting reimbursement and healthcare-system pressures in selected markets. At the same time, Cochlear increased Research and Development spending by 15%.

FY27 Guidance and Cost Actions

Cochlear expects about A$40 million of run-rate cost savings to benefit FY27. Management guided to low single-digit constant-currency revenue growth and underlying net profit of A$330 million to A$350 million, with gross margin expected to remain broadly similar to FY26. The guidance therefore assumes a measured improvement in earnings rather than a rapid margin reset.

Key Risks and Watch Points

The main variables are margin stability, manufacturing efficiency, reimbursement settings and the pace of Nexa adoption. Currency movements remain relevant because Cochlear earns most of its revenue outside Australia while reporting in Australian dollars. In FY27, attention is likely to remain on whether cost savings are delivered, gross margin stabilises and services growth continues alongside the Nexa rollout.

Key Insights

Cochlear enters FY27 with a recently launched implant platform, a growing services Business and a defined cost programme, but its financial outcome still depends on margin recovery and regional Demand conditions. The most useful indicators will be gross margin, services revenue, Nexa mix, reimbursement trends and the delivery of the expected A$40 million run-rate savings.